Links to Exploration step
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Local therapy for rhabdomyosarcoma of the hands and feet: Is amputation necessary? A report from the Children's Oncology Group</title><author><name sortKey="La, Trang H" sort="La, Trang H" uniqKey="La T" first="Trang H." last="La">Trang H. La</name><affiliation><nlm:aff id="A1">Department of Radiation Oncology, Stanford University, Stanford, CA</nlm:aff></affiliation></author><author><name sortKey="Wolden, Suzanne L" sort="Wolden, Suzanne L" uniqKey="Wolden S" first="Suzanne L." last="Wolden">Suzanne L. Wolden</name><affiliation><nlm:aff id="A2">Department of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY</nlm:aff></affiliation></author><author><name sortKey="Su, Zheng" sort="Su, Zheng" uniqKey="Su Z" first="Zheng" last="Su">Zheng Su</name><affiliation><nlm:aff id="A1">Department of Radiation Oncology, Stanford University, Stanford, CA</nlm:aff></affiliation></author><author><name sortKey="Linardic, Corinne" sort="Linardic, Corinne" uniqKey="Linardic C" first="Corinne" last="Linardic">Corinne Linardic</name><affiliation><nlm:aff id="A3">Department of Pediatric Hematology-Oncology, Duke University, Durham, NC</nlm:aff></affiliation></author><author><name sortKey="Randall, R Lor" sort="Randall, R Lor" uniqKey="Randall R" first="R. Lor" last="Randall">R. Lor Randall</name><affiliation><nlm:aff id="A4">Department of Orthopaedics, University of Utah, Salt Lake City, UT</nlm:aff></affiliation></author><author><name sortKey="Hawkins, Douglas S" sort="Hawkins, Douglas S" uniqKey="Hawkins D" first="Douglas S." last="Hawkins">Douglas S. Hawkins</name><affiliation><nlm:aff id="A5">Division of Hematology/Oncology, University of Washington School of Medicine, Seattle, WA</nlm:aff></affiliation></author><author><name sortKey="Donaldson, Sarah S" sort="Donaldson, Sarah S" uniqKey="Donaldson S" first="Sarah S." last="Donaldson">Sarah S. Donaldson</name><affiliation><nlm:aff id="A1">Department of Radiation Oncology, Stanford University, Stanford, CA</nlm:aff></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">20646853</idno><idno type="pmc">3075377</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3075377</idno><idno type="RBID">PMC:3075377</idno><idno type="doi">10.1016/j.ijrobp.2010.01.053</idno><date when="2010">2010</date><idno type="wicri:Area/Pmc/Corpus">002853</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">002853</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Local therapy for rhabdomyosarcoma of the hands and feet: Is amputation necessary? A report from the Children's Oncology Group</title><author><name sortKey="La, Trang H" sort="La, Trang H" uniqKey="La T" first="Trang H." last="La">Trang H. La</name><affiliation><nlm:aff id="A1">Department of Radiation Oncology, Stanford University, Stanford, CA</nlm:aff></affiliation></author><author><name sortKey="Wolden, Suzanne L" sort="Wolden, Suzanne L" uniqKey="Wolden S" first="Suzanne L." last="Wolden">Suzanne L. Wolden</name><affiliation><nlm:aff id="A2">Department of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY</nlm:aff></affiliation></author><author><name sortKey="Su, Zheng" sort="Su, Zheng" uniqKey="Su Z" first="Zheng" last="Su">Zheng Su</name><affiliation><nlm:aff id="A1">Department of Radiation Oncology, Stanford University, Stanford, CA</nlm:aff></affiliation></author><author><name sortKey="Linardic, Corinne" sort="Linardic, Corinne" uniqKey="Linardic C" first="Corinne" last="Linardic">Corinne Linardic</name><affiliation><nlm:aff id="A3">Department of Pediatric Hematology-Oncology, Duke University, Durham, NC</nlm:aff></affiliation></author><author><name sortKey="Randall, R Lor" sort="Randall, R Lor" uniqKey="Randall R" first="R. Lor" last="Randall">R. Lor Randall</name><affiliation><nlm:aff id="A4">Department of Orthopaedics, University of Utah, Salt Lake City, UT</nlm:aff></affiliation></author><author><name sortKey="Hawkins, Douglas S" sort="Hawkins, Douglas S" uniqKey="Hawkins D" first="Douglas S." last="Hawkins">Douglas S. Hawkins</name><affiliation><nlm:aff id="A5">Division of Hematology/Oncology, University of Washington School of Medicine, Seattle, WA</nlm:aff></affiliation></author><author><name sortKey="Donaldson, Sarah S" sort="Donaldson, Sarah S" uniqKey="Donaldson S" first="Sarah S." last="Donaldson">Sarah S. Donaldson</name><affiliation><nlm:aff id="A1">Department of Radiation Oncology, Stanford University, Stanford, CA</nlm:aff></affiliation></author></analytic><series><title level="j">International journal of radiation oncology, biology, physics</title><idno type="ISSN">0360-3016</idno><idno type="eISSN">1879-355X</idno><imprint><date when="2010">2010</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><sec id="S1"><title>Purpose</title><p id="P1">To evaluate the outcome of children with rhabdomyosarcoma (RMS) of the hand or foot treated with surgery and/or local radiotherapy (RT).</p></sec><sec sec-type="methods" id="S2"><title>Methods</title><p id="P2">Forty-eight patients with non-metastatic RMS of the hand or foot were enrolled on Intergroup Rhabdomyosarcoma Study Group III, IV-Pilot, and IV. Patients received multi-agent chemotherapy with surgery and/or RT. Twenty-four patients (50%) underwent surgery without local RT, of whom 4 had complete resection and 20 had an amputation. The remaining 24 patients (50%) underwent local RT, of whom 2 required RT for microscopic residual disease following prior amputation. Median follow-up for surviving patients is 9.7 years.</p></sec><sec id="S3"><title>Results</title><p id="P3">Actuarial 10-year local control is 100%; 10-year event-free (EFS) and overall survival (OS) are 62% and 63%, respectively. Poor prognostic factors for recurrence include gross residual (Group III) disease and nodal involvement (p=0.01 and 0.05, respectively). More patients in the RT group had alveolar histology, Group III disease, and nodal involvement, as compared to the surgery group. There is no difference in 10-year EFS (57% vs. 66%) or OS (63% vs. 63%) between patients who underwent surgery or local RT. Among relapsing patients, there are no long-term survivors. No secondary malignancies have been observed.</p></sec><sec id="S4"><title>Conclusions</title><p id="P4">Despite having high-risk features, patients treated with local RT achieved excellent local control. Complete surgical resection without amputation is difficult to achieve in the hand or foot. Therefore, we recommend either definitive RT or surgical resection which maintains form and function as primary local therapy rather than amputation in patients with hand or foot rhabdomyosarcoma.</p></sec></div></front></TEI><pmc article-type="research-article" xml:lang="EN"><pmc-comment>The publisher of this article does not allow downloading of the full text in XML form.</pmc-comment>
<pmc-dir>properties manuscript</pmc-dir>
<front><journal-meta><journal-id journal-id-type="nlm-journal-id">7603616</journal-id><journal-id journal-id-type="pubmed-jr-id">4036</journal-id><journal-id journal-id-type="nlm-ta">Int J Radiat Oncol Biol Phys</journal-id><journal-title>International journal of radiation oncology, biology, physics</journal-title><issn pub-type="ppub">0360-3016</issn><issn pub-type="epub">1879-355X</issn></journal-meta><article-meta><article-id pub-id-type="pmid">20646853</article-id><article-id pub-id-type="pmc">3075377</article-id><article-id pub-id-type="doi">10.1016/j.ijrobp.2010.01.053</article-id><article-id pub-id-type="manuscript">NIHMS179324</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Local therapy for rhabdomyosarcoma of the hands and feet: Is amputation necessary? A report from the Children's Oncology Group</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>La</surname><given-names>Trang H.</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Wolden</surname><given-names>Suzanne L.</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="A2">2</xref></contrib><contrib contrib-type="author"><name><surname>Su</surname><given-names>Zheng</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Linardic</surname><given-names>Corinne</given-names></name><degrees>MD, PhD</degrees><xref ref-type="aff" rid="A3">3</xref></contrib><contrib contrib-type="author"><name><surname>Randall</surname><given-names>R. Lor</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="A4">4</xref></contrib><contrib contrib-type="author"><name><surname>Hawkins</surname><given-names>Douglas S.</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="A5">5</xref></contrib><contrib contrib-type="author"><name><surname>Donaldson</surname><given-names>Sarah S.</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="A1">1</xref></contrib></contrib-group><aff id="A1"><label>1</label>Department of Radiation Oncology, Stanford University, Stanford, CA</aff><aff id="A2"><label>2</label>Department of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY</aff><aff id="A3"><label>3</label>Department of Pediatric Hematology-Oncology, Duke University, Durham, NC</aff><aff id="A4"><label>4</label>Department of Orthopaedics, University of Utah, Salt Lake City, UT</aff><aff id="A5"><label>5</label>Division of Hematology/Oncology, University of Washington School of Medicine, Seattle, WA</aff><author-notes><corresp id="CR1">Corresponding author: Sarah S. Donaldson MD Department of Radiation Oncology Stanford University Cancer Center 875 Blake Wilbur Drive MC 5847 Stanford, CA 94305 Phone: (650) 723-6195 Fax: (650) 723-4812 <email>sarah2@stanford.edu</email></corresp></author-notes><pub-date pub-type="nihms-submitted"><day>22</day><month>2</month><year>2011</year></pub-date><pub-date pub-type="epub"><day>18</day><month>6</month><year>2010</year></pub-date><pub-date pub-type="ppub"><day>1</day><month>5</month><year>2011</year></pub-date><pub-date pub-type="pmc-release"><day>1</day><month>5</month><year>2012</year></pub-date><volume>80</volume><issue>1</issue><fpage>206</fpage><lpage>212</lpage><permissions><copyright-statement>© 2010 Elsevier Inc. All rights reserved</copyright-statement><copyright-year>2010</copyright-year></permissions><abstract><sec id="S1"><title>Purpose</title><p id="P1">To evaluate the outcome of children with rhabdomyosarcoma (RMS) of the hand or foot treated with surgery and/or local radiotherapy (RT).</p></sec><sec sec-type="methods" id="S2"><title>Methods</title><p id="P2">Forty-eight patients with non-metastatic RMS of the hand or foot were enrolled on Intergroup Rhabdomyosarcoma Study Group III, IV-Pilot, and IV. Patients received multi-agent chemotherapy with surgery and/or RT. Twenty-four patients (50%) underwent surgery without local RT, of whom 4 had complete resection and 20 had an amputation. The remaining 24 patients (50%) underwent local RT, of whom 2 required RT for microscopic residual disease following prior amputation. Median follow-up for surviving patients is 9.7 years.</p></sec><sec id="S3"><title>Results</title><p id="P3">Actuarial 10-year local control is 100%; 10-year event-free (EFS) and overall survival (OS) are 62% and 63%, respectively. Poor prognostic factors for recurrence include gross residual (Group III) disease and nodal involvement (p=0.01 and 0.05, respectively). More patients in the RT group had alveolar histology, Group III disease, and nodal involvement, as compared to the surgery group. There is no difference in 10-year EFS (57% vs. 66%) or OS (63% vs. 63%) between patients who underwent surgery or local RT. Among relapsing patients, there are no long-term survivors. No secondary malignancies have been observed.</p></sec><sec id="S4"><title>Conclusions</title><p id="P4">Despite having high-risk features, patients treated with local RT achieved excellent local control. Complete surgical resection without amputation is difficult to achieve in the hand or foot. Therefore, we recommend either definitive RT or surgical resection which maintains form and function as primary local therapy rather than amputation in patients with hand or foot rhabdomyosarcoma.</p></sec></abstract><kwd-group><kwd>Rhabdomyosarcoma</kwd><kwd>local control</kwd><kwd>radiotherapy</kwd><kwd>amputation</kwd></kwd-group><contract-num rid="CA1">U10 CA098543-08
||CA</contract-num><contract-num rid="CA1">U10 CA072989-06
||CA</contract-num><contract-num rid="CA1">U10 CA030969-22
||CA</contract-num><contract-num rid="CA1">U10 CA029139-22
||CA</contract-num><contract-num rid="CA1">U10 CA024507-26
||CA</contract-num><contract-num rid="CA1">U10 CA013539-30
||CA</contract-num><contract-sponsor id="CA1">National Cancer Institute : NCI</contract-sponsor></article-meta></front></pmc></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/Pmc/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002853 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd -nk 002853 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= LymphedemaV1
|flux= Pmc
|étape= Corpus
|type= RBID
|clé=
|texte=
}}
| This area was generated with Dilib version V0.6.31. |  |